Sucampo Pharmaceuticals SCMP announced Wednesday that
it has received a $10 million milestone payment from Takeda
Pharmaceutical Company Limited (Takeda), pursuant to the existing
collaboration and license agreement between SPI and Takeda. The
milestone payment was triggered by the commercial launch of AMITIZA®
(lubiprostone) (24 mcg daily) in the United States for the treatment of
opioid-induced constipation (OIC) in adult patients with chronic,
non-cancer pain. The effectiveness of AMITIZA in the treatment of
opioid-induced constipation in patients taking diphenylheptane opioids
(e.g., methadone) has not been established.
This is the third indication for AMITIZA, which is also approved in the
U.S. for the treatment of chronic idiopathic constipation (CIC) in
See full press release
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in